Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens.
Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens.
复制标题
DOI：
10.2147/idr.s6961
复制
发表时间：
2010-01-01
影响因子：
3.9
通讯作者：
Weis, Florian
中科院分区：
文献类型：
--
作者：
Beiras-Fernandez, Andres;Vogt, Ferdinand;Weis, Florian
本文综述了革兰氏阳性菌耐药的历史背景，并详细介绍了新型脂肽类抗生素达托霉素。药理学和药代动力学方面的审查和目前的临床应用达托霉素。达托霉素似乎是治疗复杂皮肤和皮肤结构感染、感染性右心内膜炎和革兰氏阳性菌引起的菌血症的可靠药物。其独特的作用机制和低耐药性特征，以及其快速杀菌作用使其成为多重耐药球菌中万古霉素的有利替代品。达托霉素在治疗假体材料感染、骨髓炎和泌尿生殖道感染中的作用需要在随机临床试验中进行评价。
The aim of this review is to summarize the historical background of drug resistance of Gram-positive pathogens as well as to describe in detail the novel lipopeptide antibiotic daptomycin. Pharmacological and pharmacokinetic aspects are reviewed and the current clinical use of daptomycin is presented. Daptomycin seems to be a reliable drug in the treatment of complicated skin and skin structure infections, infective right-sided endocarditis, and bacteremia caused by Gram-positive agents. Its unique mechanism of action and its low resistance profile, together with its rapid bactericidal action make it a favorable alternative to vancomycin in multi-drug resistant cocci. The role of daptomycin in the treatment of prosthetic material infections, osteomyelitis, and urogenital infections needs to be evaluated in randomized clinical trials.